The clinical trial to treat primary and secondary liver cancer with the drug ALN-VSP from Alnylam Pharmaceuticals is ready to start phase 2 using its highest dose. ALN-VSP is a drug that limits the ability of cancer cells to make proteins used to form their blood vessels. This will lead to less blood flow to … Read more